Tests empagliflozin in adults with advanced chronic kidney disease
Tests empagliflozin, given before or after placebo, in adults with advanced kidney disease.
Plain-language title generated from the registry record
Registry title: Effect of Empagliflozin in Patients With eGFR Between 10 and 20 ml/Min/1.73m2
Key facts
- Where
- Nice, FranceSee the site
- Phase
- Phase 4
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT07074418, who can take part
Where in France
- CHU Nice - Hôpital Pasteur 2Nice, FranceTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Centre Hospitalier Universitaire de Nice
- Trial code
- NCT07074418
- Record updated
- 10 September 2026
- Original description
The proximal tubule remains the main site for sodium reabsorption in patients with advanced renal failure. The investigators therefore hypothesize that SGLT2i should still exert a significant natriuretic effect in patients with eGFR below 20 ml/min/1.73m2, and therefore should still decrease proteinuria with a potential renal protective effect.Read full original descriptionShow less
Effect of Empagliflozin in Patients With eGFR Between 10 and 20 ml/Min/1.73m2 - EMPA [10-20]
The proximal tubule remains the main site for sodium reabsorption in patients with advanced renal failure. The investigators therefore hypothesize that SGLT2i should still exert a significant natriuretic effect in patients with eGFR below 20 ml/min/1.73m2, and therefore should still decrease proteinuria with a potential renal protective effect.
Inclusion: type 2 diabetics,; age between 18 and 80 years,; RAS blockade at maximal tolerated dosage for 1 month,; eGFR (CKD-EPI) between 10 and 20 ml/min/1.73m2,; UACR > 300mg/g creatinine and UPCR > 500mg/g creatinine,; office systolic blood pressure > 110 mmHg,; stable dosage of antihypertensive drugs and diuretics for 1 month; for women of child-bearing age, an effective contraception (estroprogestative pill, contraceptive implant, IUD, condoms or tubal ligation) should be used for more than one month before the inclusion in the study. A urine pregnancy test (βHCG in urines) will be performed.
Exclusion: participation in another clinical study with an investigational medicinal product (IMP) administered during the month before screening,; any medical condition that, in the opinion of the investigator makes the participant not suitable for inclusion,; history of ketoacidosis in the past while on empagliflozin or any other SGLT2i class drugs,; known hypersensitivity or intolerance to empagliflozin or any of the excipients of the product,; judgment by the investigator that the participant should not participate in the study if the participant is unlikely to comply with study procedures, restrictions, and requirements,; no social insurance,; unwilling to give informed consent,; vulnerable persons (minors, adults under guardianship or trusteeship, pregnant women, persons deprived of their liberty, persons unable to speak French).